New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
08:17 EDTISIS, BIIBIsis Pharmaceuticals data compelling, says BMO Capital
BMO Capital believes that data from a Phase I test of Isis' (ISIS) and Biogen's (BIIB) ISIS-SMN-Rx, an antisense oligonucleotide, for children with spinal muscular atrophy, suggests that the drug has a substantial clinical benefit. The firm raised its price target on Isis to $22 from $17 and maintains an Outperform rating.
News For ISIS;BIIB From The Last 14 Days
Check below for free stories on ISIS;BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
14:30 EDTBIIBBiogen technical remarks ahead of earnings
Subscribe for More Information
July 21, 2014
07:37 EDTBIIBBiogen July weekly volatility elevated into Q2 and outlook
Biogen July weekly call option implied volatility is at 55, August is at 34, October is at 36; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement into the expected release of Q2 on July 23.
July 17, 2014
07:10 EDTISISIsis Pharmaceuticals begins Phase 2 study of candidate for high lipoprotein(a)
Subscribe for More Information
July 16, 2014
07:14 EDTISISIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
July 9, 2014
07:23 EDTBIIBBiogen price target raised to $375 from $325 at RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use